Clinical Trial Update: Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ulipristal acetate for anemia associated with uterine fibroids has been withdrawn with no results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Uterine Fibroids

Drugs mentioned

• Ulipristal acetate (ulipristal acetate)

Snippet

Sponsor: Watson Pharmaceuticals | Conditions: Leiomyomas | Phase 3 | Status: WITHDRAWN